How a struggling biotech company became a university ‘spin-in’

by | Sep 10, 2024 | Uncategorized | 0 comments

Nature, Published online: 10 September 2024; doi:10.1038/d41586-024-02627-8

Despite meeting a clinical and societal need for snakebite antivenom development, VenomAb folded after four years, propelling co-founder Andreas Laustsen-Kiel to a role that combines entrepreneurship and academia.

Archive Posts

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.